Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Press release: Availability of the Q3 2025 Aide mémoire
01:00am, Wednesday, 24'th Sep 2025
Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Thi
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
02:03pm, Tuesday, 23'rd Sep 2025
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Press Release: Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
01:00am, Tuesday, 23'rd Sep 2025
Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK ex
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
01:06pm, Monday, 22'nd Sep 2025
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
12:31pm, Monday, 22'nd Sep 2025
The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
01:00am, Monday, 22'nd Sep 2025
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
12:30am, Monday, 22'nd Sep 2025
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig
Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
01:00am, Wednesday, 17'th Sep 2025
EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary e
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
01:46pm, Thursday, 11'th Sep 2025
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
01:00am, Thursday, 11'th Sep 2025
Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
08:00am, Wednesday, 10'th Sep 2025
Mandy Moore joins Elaine Welteroth, Gaby Dalkin, Katya Echazarreta, and Shawn Johnson East to share their personal respiratory syncytial virus (RSV) stories and why they chose BEYFORTUS to help prote
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
01:00am, Wednesday, 10'th Sep 2025
Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
04:40pm, Tuesday, 09'th Sep 2025
Sanofi (NASDAQ:SNY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Paul Hudson - CEO & Director Conference Call Participants Sarita Kapila
Sanofi market value tanks following weak results on eczema drug trials
02:56pm, Thursday, 04'th Sep 2025
Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab
Why Is Sanofi Stock Falling Thursday?
02:36pm, Thursday, 04'th Sep 2025
On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fre
